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ABSTRACT
We investigated the antitumor effects of the combination of matrine-a purified alkaloid extracted from Sophora flavescence-
and 5-fluorouracil (5-FU) on SW480 cells. This combination inhibited the growth of SW480 cells in a synergistic or additive 
manner by disrupting their progression through the cell cycle. Exposure of SW480 cells to matrine and 5-FU was followed 
by an increased rate of expression for caspase-3, caspase-9 and poly-ADP ribose polymerase (PARP) and inhibited the 
subcutaneous transplantation of SW480 tumors into Balb/c nude mice. Histopathological analysis showed that this 
effect was most pronounced in the spleens of treated animals. Typical cytotoxic effects observed in 5-FU-treated mice 
included fibrosis and lymphopenia, whereas in mice treated with 5-FU combined with matrine, the spleen ultrastructure 
remained intact. These findings indicate that matrine may enhance the therapeutic effectiveness of 5-FU in SW480 tumors 
by enhancing apoptosis and overcome the threat to immunocompetence associated with 5-FU.
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ABSTRAK
Kami mengkaji kesan antitumor daripada gabungan matrin - alkaloid yang ditulenkan diekstrak daripada Sophora 
flavescence dan 5-fluorourasil (5-FU) pada sel SW480. Gabungan ini menghalang pertumbuhan sel SW480 secara sinergi 
atau tambahan dengan mengganggu perkembangan mereka melalui kitaran sel. Pendedahan sel SW480 kepada matrine 
dan 5-FU diikuti dengan kadar peningkatan ekspresi untuk caspase-3, caspase-9 dan poli-ADP ribosa polimerase (PARP) 
dan menghalang pemindahan subkutaneus tumor SW480 ke tikus bogel  Balb/c.  Analisis histopatologi menunjukkan 
bahawa ini memberi kesan paling ketara dalam limpa haiwan yang dirawat. Kesan sitotoksik biasa diperhatikan dalam 
tikus 5-FU-dirawat termasuk fibrosis dan limfofenia, manakala pada tikus yang dirawat dengan 5-FU digabungkan dengan 
matrin, ultrastruktur limpa kekal utuh. Penemuan ini menunjukkan bahawa  matrin boleh meningkatkan keberkesanan 
terapeutik 5-FU dalam tumor SW480 dengan meningkatkan apoptosis dan mengatasi ancaman kepada kecekapanimmuno 
yang dikaitkan dengan 5-FU.
Kata kunci: Gabungan kemoterapi; kanser kolorektal; sitotoksiti; Sophora flavescence; 5-fluorourasil
INTRODUCTION
Colorectal cancer (CRC) is a major cause of death from 
cancer worldwide. In China, CRC ranks fifth among cancer 
deaths and its occurence is increasing rapidly (Zhao et al. 
2010). The 5-year survival rate associated with current 
treatments hovers around 50%. The chemotherapeutic 
agent 5-fluorouracil (5-FU) has been the first choice for 
chemotherapy and the basis of combination chemotherapy 
for CRC for many years. As a single agent, 5-FU has a 
considerable curative effect. However, it is highly toxic. 
Consequently, it is usually used in combination with other 
chemotherapeutic agents.
 Sophora flavescens is a plant that is typically used 
in traditional Chinese medicine to treat individuals 
with viral hepatitis, enteritis, cancer, viral myocarditis, 
gastrointestinal hemorrhage, and skin diseases (colpitis, 
psoriasis and eczema) (Liu et al. 2006; Luo et al. 2007; 
Yamazaki 2000). Matrine, a purified alkaloid extracted 
from the dried roots of S flavescence, has demonstrated 
anti-tumor activity both in vitro and in vivo (Dai et al. 2009; 
Jiang et al. 2007). The ability to inhibit tumor growth while 
enhancing immune function and improving the patient’s 
quality of life has been demonstrated in numerous studies 
(Chen et al. 2006; Crew & Neugut 2006), including studies 
in the cervix, stomach, breast and lung, as well as in 
hepatocellular carcinoma, leukemia and multiple myeloma 
(Dai et al. 2005; Han et al. 2010; Yu et al. 2009; Zhang et 
al. 2007). The mechanisms for its antitumor activity appear 
to be the inhibition of cell proliferation and induction of 
apoptosis (Ma et al. 2008). We examined the antitumor 
effect of combining the matrine with 5-FU on human CRC 
cells both in vitro and in vivo. The possible roles and 
mechanism of matrine in the treatment of CRC were also 
explored.
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EXPERIMENTAL DETAILS
MATERIALS AND METHODS
All chemicals used in this study were purchased from the 
Sigma Chemical Company (St Louis, Mo, USA) unless 
otherwise stated. Matrine and 5-FU were purchased from 
Yanchi County Pharmaceutical Company, Ltd (China) and 
the Shanghai Xudong Haipu Pharmaceutical Company, Ltd 
(China). A 40-μM/mL solution of matrine dissolved it in 
0.9% sodium chloride was frozen at –20℃. Antibodies to 
cleaved caspase-3, cleaved Poly-ADP Ribose Polymerase 
(PARP), cleaved caspase-9 and β-actin were purchased 
from Cell Signaling Technology (Danvers, Mass, USA) and 
Santa Cruz Biotechnology (Santa Cruz, Calif, USA). SW480 
was purchased from American Type Culture Collection 
(ATCC) (CCL228; ATCC, Manassas, Va, USA) and cultured 
in RPMI 1640 containing 10% fetal bovine serum (FBS), 
streptomycin 100 μg/mL and penicillin 100 U/mL at 37°C 
in a 5% CO2 incubator.
GENERAL PROCEDURE 
Methyl thiazolyl tetrazolium (MTT) assay; Flow cytometric 
analysis of cell cycle; Western blotting analysis. 
DETECTION METHOD 
In vivo tumor-growth assay. Female BALB/c athymic nude 
mice aged 4 to 6 weeks old were purchased from the Center 
of Experimental Animals (Southern Medical University, 
China). Animal experiments were conducted in accordance 
with the Animal Research Committee Guidelines of 
Southern Medical University (SCXK(Yue) 2006-0015, 
2006B023). SW480 cells were injected subcutaneously at a 
concentration of 2×106 into the left flank and right inguinal 
fold of 32 nude mice. The nude mice were then randomized 
into one of 4 groups: Control group: Animals that received 
an intraperitoneal (IP) injection of 0.9% sodium chloride; 
Matrine group: Animals that received matrine 30 mg/kg 
daily; 5-FU group: Animals that received 5-FU 30 mg/
kg twice weekly; and Matrine + 5-FU group: Animals 
that received matrine 30 mg/kg daily and 5-FU 30 mg/kg 
twice weekly. Xenografts were measured using a vernier 
caliper. Both long (a) and short (b) diameters measured 
at 7-day intervals were used to calculate the xenograft 
volume (Mizutani et al. 2004): Volume (V) = a × b2/2 
On day 28 after each injection, the mice were sacrificed 
and the xenografts were harvested to calculate the tumor 
growth inhibition rate: Inhibition rate (%) = (1 – (mass of 
xenograft in experimental group ÷ mass of xenograft in 
control group)) × 100%
 Body weights were measured at the start of each 
experiment and on the last day of each treatment 
period. Histopathological and morphological analyses 
of the tumors were performed. Statistical analysis: 
Data were analyzed using SPSS 13.0 and expressed as 
the mean±standard deviation (SD). One-way analysis 
of variance (ANOVA), Welch statistic tests or factorial-
designed ANOVA were applied. For multiple comparisons, 
least significant difference or Games Howell was used, 
respectively, according to the homogeneity of variances.
RESULTS AND DISCUSSION
Inhibitory effects on SW480 cell proliferation was shown 
in Table 1; Control of SW480 cell progression through the 
cell cycle was shown in Table 2. 
 Caspase expression increased after exposure to the 
combination of matrine and 5-FU (Figure 1) in Western 
blot analysis. These results indicated that matrine and 
5-FU may induce apoptosis in SW480 cells by activating 
the caspase-3 and caspase-9 pathways. 
 Changes in tumor volume and weight demonstrated 
that xenografts had the fastest growth rate in controls. 
Matrine or 5-FU inhibited tumor growth at rates of 13.71% 
and 63.07% respectively. Treatment with a combination of 
matrine and 5-FU at the same doses used in monotherapy 
had a greater inhibitory effect than treatment with either 
agent alone (Figure 2(a), 2(b)), with inhibition rates rising 
dramatically to 80.58%. These agents also appeared to have 
an effect on body weight, which decreased significantly 
with 5-FU monotherapy (p<.05) then increased significantly 
with matrine/5-FU combination therapy (p<.05) (Figure 
TABLE 1. The effect of matrine combined with 5-FU on the inhibition of growth in SW480 cells (n=3)
Time
(h)
5-FU Growth inhibition rate (%) 　
F
　
P(mg/mL) 5-FU 5-FU+Matrine
24 3.125
6.25
12.5
10.66±1.92
21.22±2.24
23.71±3.40
24.18±7.63*
36.20±6.11*
43.57±5.36*
8.667
15.865
29.429
.041
.016
.006
48 3.125
6.25
12.5
21.25±3.28
31.12±0.22
57.36±5.39
59.30±3.44*
70.76±3.30*
91.89±3.06*
360.018
431.173
92.856
< .001
< .001
.001
72
　
3.125
6.25
12.5
34.12±4.18
49.67±6.98
65.39±6.16
53.26±3.49*
81.13±0.97*
89.58±1.27*
37.132
23.745
44.326
.004
.008
.003
*p < .05 compared with 5-FU alone
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2(c)). Histopathological analysis showed large areas of 
necrosis and apoptosis of tumors in mice treated with 
combination therapy. The 5-FU group demonstrated a 
diffuse distribution of necrosis and relatively few apoptotic 
cells compared with the combination matrine/5-FU group, 
which demonstrated an increased number of apoptotic cells 
in some areas of the tumor (Figure 2(d)) compared with 
the 5-FU monotherapy group.
 It has been reported that matrine shows antitumor 
activity in many types of cancer. It has also been shown 
that the combination of matrine and cisplatin is superior to 
cisplatin alone in patients with non–small-cell lung cancer 
accompanied by subclinical pleural metastasis (Yang et al. 
2012). It has been suggested that matrine inhibits tumor 
growth by modulating genes and proteins that participate 
in apoptosis or facilitate proliferation, such as N-ras, p53 
and the caspases (Jiang et al. 2007; Zhang et al. 2007). 
In a recent study, it was reported that matrine inhibits the 
growth of gastric carcinoma by up-regulating Beclin 1 and 
inducing autophagy (Zhang et al. 2011). Matrine can stop 
K-562 cells from entering the S-phase of the cell cycle by 
inhibiting the expression of myc (Zhang et al. 2001). In 
this study, we demonstrated that low doses of matrine can 
enhance the inhibitory effects of 5-FU in SW480 cells by 
contributing in a synergistic or additive manner to blocking 
progression through specific phases of the cell cycle. 
 Apoptosis is a key target for new anti-cancer therapies. 
This form of cell death is coordinated by a network of genes 
and gene products involved in both caspase-dependent and 
caspase-independent pathways (Broker et al. 2005). The 
caspases constitute a unique class of aspartate-specific 
proteases that serve as central components of the apoptotic 
response. There are 2 types of caspases: Initiator caspases 
(caspases 2, 8, 9 and 10) and effector caspases (caspases 
3, 7 and 6) Lopez-Hernandez et al. 2003). We found that 
matrine and 5-FU may induce apoptosis in SW480 cells 
by activating caspase-3 and caspase-9. We found that 
the combination of matrine and 5-FU had a considerably 
greater inhibitory effect on the growth of SW480 tumors 
than monotherapy with either agent. Histological analysis 
showed that this combination of agents resulted in more 
apoptotic tumor cells than other groups. Some researchers 
associate the antitumor activity of matrine with its 
immunomodulatory properties, specifically with its ability 
to activate both cellular and humoral immune responses 
(Lin et al. 2011). In the present study, we found that mice 
that received 5-FU alone were more likely to exhibit 
diarrhea, stiff movements and weakness compared with 
those who received combination therapy. By contrast, 
the rate of weight loss decreased and the quality of life 
improved in the animals that received matrine. An injection 
of Sophora can reduce the toxicity and adverse effects of 
chemotherapy (Zhu et al. 2009). Furthermore, matrine 
may be able to inhibit the production of tumor necrosis 
factor-α and interleukin-6 in murine macrophages and 
prevent cachexia-related symptoms associated with 
TABLE 2. Changes in distribution of SW480 cells throughout the cell cycle (n=3)
Group Cell cycle phase (%)
G0/G1 S G2/M
Control 45.03±1.89 41.10±4.29 13.90±2.36
Matrine 57.47±1.66* 30.87±3.04* 11.70±1.47
5-FU 60.11±1.53* 29.63±1.46* 10.26±0.66*
Matrine+5-FU 72.70±1.05* 16.67±0.47* 10.63±1.52*
F 157.864 40.136 3.072
P < .001 < .001 0. 091
*p< .05 vs control group
FIGURE 1. Activation of the caspase pathway in Western blot
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colon adenocarcinoma in mice (Zhang et al. 2008). These 
findings suggest that matrine not only possesses antitumor 
effects but can also enhance the antitumor activity of 
chemotherapeutic drugs, including 5-FU and decrease the 
number and severity of side effects.
CONCLUSION
Matrine may enhance the therapeutic effectiveness of 5-FU 
in SW480 tumors by enhancing apoptosis and release the 
side effects associated with 5-FU. Our results also suggested 
a potential clinical use for matrine/5-FU combination 
therapy on CRC.
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